About Cerebricon
Cerebricon is a company based in Kuopio (Finland) founded in 2000 was acquired by Charles River Laboratories in August 2009. The company has 52 employees as of April 04, 2024. Cerebricon operates in a competitive market with competitors including Wave Neuro, Cerca Insights, Afraxis, Nemosia and Brain Trust Bio, among others.
- Headquarter Kuopio, Finland
- Employees 52 as on 04 Apr, 2024
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Charles River Laboratories India Private Limited
- Date of Incorporation 08 Oct, 2008
- Jurisdiction Bangalore, Karnataka, India
-
Annual Revenue
$9.08 M (USD)6.48as on Mar 31, 2021
-
Net Profit
$209.73 K (USD)45.48as on Mar 31, 2021
-
EBITDA
$231.49 K (USD)-25.9as on Mar 31, 2021
-
Latest Funding Round
Not available
- Investors
-
Employee Count
52
as on Apr 04, 2024
-
Acquired by
Charles River Laboratories
(Aug 06, 2009)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cerebricon
Detailed funding history for Cerebricon
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Cerebricon
Cerebricon has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Charles River Laboratories.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provider of drug discovery and preclinical development services
|
Locked | Locked | Locked |
Investor details for Cerebricon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cerebricon
Investment portfolio details for Cerebricon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cerebricon
Detailed financials for Cerebricon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cerebricon Comparisons
Peer comparison for Cerebricon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cerebricon
Cerebricon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Wave Neuro, Cerca Insights, Afraxis, Nemosia and Brain Trust Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Preclinical services to neurological science are provided.
|
|
| Locked | Locked | Locked |
Provides preclinical services in behavioral pharmacology for research and development.
|
|
| Locked | Locked | Locked |
Provides comprehensive CNS pharmaceutical screening technologies for pre-clinical evaluations.
|
|
| Locked | Locked | Locked |
Preclinical services for neurological disorders are provided.
|
|
| Locked | Locked | Locked |
Provider of contract based drugs delivery services for CNS disorders
|
|
| Locked | Locked | Locked |
Preclinical development services for CNS disorders and compounds are provided.
|
Detailed competitors of Cerebricon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cerebricon
Complete news archive for Cerebricon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cerebricon
Cerebricon was founded in 2000.
Cerebricon is headquartered in Kuopio, Finland.
As of Apr 04, 2024, the latest employee count at Cerebricon is 52.
Annual revenue of Cerebricon is $9.08M as on Mar 31, 2021.
Cerebricon was established in 2000 in Kuopio, Finland, as a provider of preclinical research services targeting central nervous system (CNS) and peripheral nervous system (PNS) diseases. Operations focus on the biotechnology sector, where support is given for early-stage drug development and testing in neurological disorders. Services encompass in vivo and in vitro models, efficacy assessments, and safety evaluations, conducted primarily from the companys base in northern Europe.
Cerebricon's top competitors include Brains On-Line, Neuro-Sys and Brain Trust Bio.
Cerebricon has 1 investor. Key investors include Charles River Laboratories.